Related Experiment Video
Updated: Aug 12, 2026

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
Published on: June 15, 2020
[Heart failure--epidemic of the 21st century]
1III. interní klinika 1. LF UK a VFN, Praha.
Insights
The number of heart failure patients is rising due to longer life expectancy and better cardiovascular disease treatment. Despite advances, prognosis remains poor, driving research into new therapies like cardiac resynchronization therapy and gene therapy.
Area of Science:
- Cardiology
- Public Health
Context:
- Chronic heart failure prevalence is increasing globally, particularly in developed nations.
- Factors include improved cardiovascular disease management and increased life expectancy.
- In the Czech Republic, cardiovascular mortality decreased 30% and life expectancy rose 4 years in 15 years.
Purpose:
- To summarize the current state of heart failure prevalence, incidence, and treatment.
- To highlight the persistent challenges in heart failure prognosis.
- To introduce emerging therapeutic avenues.
Summary:
- Heart failure affects approximately 1.5% of the general population (150,000 in the Czech Republic), with an annual incidence of 0.4% (40,000 new cases).
- Prevalence significantly increases with age, and the aging population is expected to further drive this rise.
- Standard treatments like ACE inhibitors and beta-blockers have improved outcomes, but mortality rates remain high, especially in advanced stages (NYHA class IV).
Impact:
- Despite pharmacotherapy advancements, over 40% of heart failure patients die within 4 years.
- One-year mortality for advanced heart failure exceeds 50%.
- Ongoing research into biventricular pacemakers (cardiac resynchronization therapy), implantable cardioverter/defibrillators, and gene/cell therapy offers future hope for improved patient outcomes.
Abstract:
Number of patients with chronic heart failure is increasing in all developed countries. The reasons are both, the improving prevention and treatment of deadly cardiovascular diseases, like acute myocardial infarction or stroke, and the increasing life expectancy. The cardiovascular mortality has declined by 30% and the average life expectancy has increased by 4 years also in the Czech Republic during the last 15 years. The prevalence of heart failure is about 1.5% in a general population, which means that there is about 150,000 patients in the Czech Republic. The annual incidence is about 0.4%, which means that there is about 40,000 new patients in the Czech Republic every year. The prevalence is increasing with age significantly. With respect to the ageing of the population it is expected that number of heart failure patients will be increasing. Based on the results of big clinical trials the treatment of heart failure has changed significantly. ACE inhibitors and beta-blockers became the first choice treatment improving not only symptoms but also mortality. In spite of all the progress in pharmacotherapy the prognosis of heart failure is still bad. Over 40% of patients will die within 4 years after making the diagnosis of heart failure and one-year mortality of patients with advanced heart failure (NYHA class IV) is over 50%. Therefore, a research of new therapeutic possibilities is still continuing. At present, a clinical significance of different devices, like biventricular cardiac pacemakers (cardiac resynchronization therapy) or implantable cardioverter/defibrillators in heart failure treatment is studied. A gene and cell therapy represents a great hope for heart failure treatment in future.
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management

